The authors sincerely thank the teams from the Center for Drug Evaluation at the NMPA for their valuable input in discussing the regulatory aspects of CAR T cell therapies in China. The authors also thank the teams from Legend Biotech and Johnson & Johnson, who helped to ensure the accuracy of the content regarding the development process and the timeline of the regulatory submission history. We also thank Pharmcube for providing access to their database, which was instrumental in gathering relevant product information.